Evidence map›Paper›PMID 26985178›Full record

ArticlePostepy dermatologii i alergologii2016

Clinicopathological analysis of recurrent basal cell carcinoma of the eyelid.

Aleksandra Iljin, Tomasz Zieliński, Bogusław Antoszewski, Stanisław Sporny

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Postepy dermatologii i alergologii, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. A retrospective study of 2228 cases with eyelid tumors.International journal of ophthalmology · 2018
    Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Aleksandra IljinDepartment of Plastic, Reconstructive and Aesthetic Surgery, Institute of Surgery, Medical University of Lodz, Lodz, Poland.
Tomasz ZielińskiDepartment of Plastic, Reconstructive and Aesthetic Surgery, Institute of Surgery, Medical University of Lodz, Lodz, Poland.
Bogusław AntoszewskiDepartment of Plastic, Reconstructive and Aesthetic Surgery, Institute of Surgery, Medical University of Lodz, Lodz, Poland.
Stanisław SpornyDepartment of Dental Pathology, Medical University of Lodz, Lodz, Poland.
Medical University of Lodz · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionBasal cell carcinoma (BCC) is the most common malignant neoplasm of the eyelids and surrounding structures, usually developing in the area of the lower lid and medial canthus. Invasive forms of BCC are connected with a high risk of recurrence, often due to incomplete excision of these lesions.

aimClinical and pathological analysis of recurrent BCCs of the eyelids and surrounding structures. MATERIAL AND

methodsWe present clinical and pathological analysis including immunohistochemical reaction to Ki-67 antigen of 19 patients (11 women, 8 men) operated for recurrent BCCs of the eyelids in 2000-2012.

resultsIn most cases, recurrences were present on the lower lid and in the medial canthus. In 15 patients the histopathological type did not change and in 4 cases it transformed into more invasive forms. The values of Ki-67 index for primary BCCs ranged between 1% and 20%, and for relapsing lesions between 11% and 48%.

conclusionsProper clinical and pathological evaluation to determine the risk of relapse in BCCs of the eyelids and surrounding structures should include the analysis of prognostic factors, in particular location and size, histopathological type and radicalness of surgical treatment of primary BCCs. Clinical and pathological analysis of patients with recurrent BCC of the eyelids and surrounding structures should be combined with the evaluation of proliferation index Ki-67, which is essential for prognosis and choice of the appropriate therapeutic method.

Indexed as

eyelidKi-67 antigenrecurrent BCC

Identifiers

PMID26985178
PMCPMC4793053
OpenAlexW2333504767

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.